Research Topics
| Mitchell MachtaySummaryAffiliation: Thomas Jefferson University Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysisMitchell Machtay
Jefferson Medical College and Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA
J Clin Oncol 26:3582-9. 2008..This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT...
Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)Mitchell Machtay
Thomas Jefferson University College of Medicine, Philadelphia, PA 19107, USA
Int J Radiat Oncol Biol Phys 69:1008-17. 2007..To determine whether the addition of recombinant human erythropoietin (Epo) could improve the outcomes of anemic patients receiving definitive radiotherapy for squamous cell carcinoma of the head and neck (SCCHN)...- Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignanciesGregory J Kubicek
Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 83:1192-7. 2012..This Phase I dose-escalation study examined the potential of bortezomib in combination with cisplatin chemotherapy and concurrent radiation in the treatment of locally advanced and recurrent HNC... - Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancerMitchell Machtay
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 59:72-7. 2004..We designed a prospective protocol to determine the feasibility, toxicity, and preliminary efficacy of a regimen of postoperative reirradiation, chemotherapy and the radioprotector amifostine after salvage head-and-neck surgery... - Signaling pathways in NSCLC as a predictor of outcome and response to therapyAnjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Lung 182:151-62. 2004..This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation... - Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynxSue S Yom
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Am J Clin Oncol 28:385-92. 2005..Future efforts may focus on the improved selection of patients who would be most likely to require early surgical intervention... - Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignanciesShannon Fogh
Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
Int J Radiat Oncol Biol Phys 77:1009-16. 2010.... 
Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinomaXinglei Shen
Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, USA
Radiat Oncol 6:17. 2011..This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC)...- Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrumentHeather A Jones
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Am J Clin Oncol 29:158-62. 2006..CONCLUSION: The HNDS is a valid measure of acute symptom distress and appears able to discriminate between the chemoradiation and radiation alone patients. There is considerable variation in symptoms that cause these patients distress... - A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignanciesEvan J Wuthrick
Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania 19107, USA
Cancer 117:5548-59. 2011..In this phase 1 trial, the authors evaluated sunitinib combined with radiation therapy (RT) for the treatment of primary or metastatic central nervous system (CNS) malignancies... - Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancerMary K Bucci
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
Am J Clin Oncol 27:595-602. 2004..LRC and survival compare favorably with other aggressive regimens for this poor-prognosis population. Further study of accelerated XRT with concurrent chemotherapy is indicated... - FDG-PET staging and importance of lymph node SUV in head and neck cancerGregory J Kubicek
Thomas Jefferson University Hospital, Philadelphia, PA, USA
Head Neck Oncol 2:19. 2010..The NCCN guidelines do not recommend FDG-PET as a part of standard workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and providing prognostic information for HNC... - Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancerMitchell Machtay
Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19104, USA
Semin Oncol 32:S9-12. 2005..Extreme caution must be exercised in designing studies of XRT dose intensification with concurrent chemotherapy... - Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiationJeffrey C Haynes
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Laryngoscope 112:1883-7. 2002..Although the relative risk is approximately doubled, the absolute risk is modest in comparison to the risk of cancer recurrence. Further study of this association and possible interventions is warranted... - Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic responseMitchell Machtay
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
J Thorac Cardiovasc Surg 127:108-13. 2004.... - A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancerPramila Rani Anne
Thomas Jefferson University Hospital, Bodine Center for Cancer Research, Philadelphia, PA 19107, USA
Int J Radiat Oncol Biol Phys 67:445-52. 2007..Intravenous amifostine 200 mg/m2 reduces xerostomia in head-and-neck cancer patients. This Phase II study evaluated subcutaneous (s.c.) amifostine in a similar patient population... - Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancerMitchell Machtay
Department of Radiation Oncology, Jefferson Medical College and the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Head Neck 31:195-201. 2009..We studied the potential prognostic significance of pretreatment 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) standardized uptake value (SUV) in squamous cell carcinoma of the head and neck (SCCHN)... - New advances in high-technology radiotherapy for head and neck cancerGregory J Kubicek
Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Hematol Oncol Clin North Am 22:1165-80, viii. 2008..Some of these advances are discussed in this article... - Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective studyRobert B Den
Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107 5097, USA
Int J Radiat Oncol Biol Phys 76:1353-9. 2010.... - Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancerAndrew Cupino
Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
Otolaryngol Head Neck Surg 137:416-21. 2007..This study evaluated the strategy of performing neck dissection (ND) without primary tumor resection prior to definitive chemoradiotherapy (CRT) for N2+ oropharynx cancer... - Gustatory impairment in patients undergoing head and neck irradiationNatasha Mirza
Department of Otolaryngology, Head and Neck Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Laryngoscope 118:24-31. 2008..To determine whether radiation alters taste function and structure... - Radiation treatment breaks and ulcerative mucositis in head and neck cancerGregory Russo
Department of Radiation Oncology, Jefferson Medical College, Philadelphia, Pennsylvania 19107 5097, USA
Oncologist 13:886-98. 2008..Continued investigation is needed to identify superior radiation treatment regimens, technology, and supportive care that reduce unplanned radiation treatment breaks with the goal of improving clinical outcomes in head and neck cancer... - Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignanciesGregory J Kubicek
Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 74:433-9. 2009..To evaluate the toxicity and response rate of bortezomib with concurrent radiotherapy and temozolomide in the treatment of patients with central nervous system malignancies... - Report on a randomized trial comparing two forms of immobilization of the head for fractionated stereotactic radiotherapyGreg Bednarz
Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
Med Phys 36:12-7. 2009..00+1.04 mm for frame. Both immobilization techniques were highly effective, but the GTC frame was more accurate. To optimize the accuracy of SRT, daily kilovolt image guidance is recommended with either immobilization system... - Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experienceMitchell Machtay
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 63:667-71. 2005..Further study of novel radiation-chemotherapy dose/fractionation regimens is warranted... - Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouseMitchell Machtay
Department of Medicine, Pulmonary, Allergy, and Critical Care Division, Thomas Jefferson University Medical Center, Philadelphia, PA 19104, USA
Radiother Oncol 81:196-205. 2006..There was also a corresponding effect on several early biomarkers of lung injury and decreased apoptosis. There were no significant effects on acute pneumonitis or tumor protection... - Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neckDavid I Rosenthal
Department of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Donner, Philadelphia, PA 19104, USA
Head Neck 24:115-26. 2002..CONCLUSIONS: A total treatment package time of <100 days is associated with improved tumor control and survival. Every effort should be made to keep the time from surgery to the completion of postoperative RT to <100 days... - Local recurrence in head and neck cancer: relationship to radiation resistance and signal transductionAnjali K Gupta
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
Clin Cancer Res 8:885-92. 2002..We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome... - Complex and controversial issues in locally advanced non-small cell lung carcinomaMitchell Machtay
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Semin Surg Oncol 21:128-37. 2003..This article summarizes the advances in the treatment of locally advanced NSCLC over the past several decades and explores some of the many remaining controversies and areas for future investigation... - Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II TrialMitchell Machtay
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
J Clin Oncol 20:3964-71. 2002..To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma... - Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patientsTheodore J Robnett
Radiation Oncology Centers, a division of Radiological Associates of Sacramento Medical Group, California, USA
Cancer J 8:263-7. 2002..DISCUSSION: Our analysis supports the hypothesis that response to chemoradiation of non-small cell lung carcinoma improves with increasing hemoglobin levels... - Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neckJay S Cooper
New York University Medical Center, New York, USA
N Engl J Med 350:1937-44. 2004..However, the combined treatment is associated with a substantial increase in adverse effects... - Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neckSharon A Spencer
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Head Neck 30:281-8. 2008.... - A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancerDavid I Rosenthal
Department of Radiation Oncology, Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
Invest New Drugs 20:343-9. 2002..We performed a Phase I study of Stealth liposomal cisplatin (SPI-077) concurrent with RT for head and neck squamous cell carcinoma (HNSCC)... - The early rad catches the tumor?Mitchell Machtay
J Clin Oncol 20:3045-7. 2002 - Combined modality therapy for non-small cell lung carcinomaMitchell Machtay
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104-4283, USA
Cancer J 8:S55-67. 2002..Targeted therapies appear promising, and expedited evaluation in Stage III NSCLC is warranted... - A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)Jeffrey D Bradley
Radiation Oncology Center, Washington University Medical Center, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 52:1173-9. 2002..Based on these data, the Radiation Therapy Oncology Group (RTOG) initiated a Phase III trial to test the efficacy of beta-interferon in poor-risk patients with Stages IIIA and IIIB non-small-cell lung carcinoma... - Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II studyDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
J Clin Oncol 23:4991-8. 2005.... - Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10William U Shipley
Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 54:1302-10. 2002.... - Phase I's, photons, and philosophies: new tactics for exploratory clinical trials of concurrent chemoradiationMitchell Machtay
J Clin Oncol 22:214-6. 2004 - Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancerBranislav Jeremic
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, D 81675 Munich, Germany
Hematol Oncol Clin North Am 18:91-100. 2004..Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease... - Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynxAndrew R Gordon
Department of Radiology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
AJNR Am J Neuroradiol 25:1092-8. 2004..01). CONCLUSION: Our results suggest that MR imaging-based tumor volumes are reliably reproducible. Such measurements may be important in predicting patient outcome, determining appropriate therapy, and conducting patient follow-up... - Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancerDavid I Rosenthal
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 1:38-45. 2006.... - Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01Benjamin Movsas
Department of Radiation Oncology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
J Clin Oncol 23:2145-54. 2005..To test the ability of the cytoprotectant, amifostine, to reduce chemoradiotherapy-induced esophagitis and evaluate its influence on quality of life (QOL) and swallowing symptoms... - Altered fractionation: a fractional benefit?Lori Wirth
Dana Farber Cancer Institute, Boston, MA 02115, USA
Lancet 368:819-21. 2006 - Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?Stuart J Wong
Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
J Clin Oncol 24:2653-8. 2006.... - Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705Jeffrey D Bradley
Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
J Clin Oncol 23:3480-7. 2005.... - Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapyAlbert S DeNittis
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, U.S.A
Am J Clin Oncol 25:93-5. 2002..No patient has had a local or neck failure. Chemoradiation plus brachytherapy offers encouraging survival and local-regional control. Further study of this regimen as an alternative or adjunct to intensity-modulated EBXRT is warranted...